Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients With Advanced Solid Tumors

NCT05835609 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT05835609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05835609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients With Advanced Solid Tumors
Lead sponsor
PharmaMar
Phase
Phase 1
Overall status
Recruiting
Start date
December 23, 2022
Completion date
October 31, 2026
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

patients with advanced solid tumors